Tuesday, June 18, 2013 12:21:00 PM
I mean, what if Pfizer or another big guy wanted Nyloxin to add to its own product offerings? Pfizer paid $3.6 billion or $14.25 per share to acquire King Pharmaceuticals, mostly for its pain medication products. NPHC seems undervalued to the EXTREME.
"Big drug companies have sought to strike mergers to strengthen their product lineups as patents expire, in what analysts have called a “patent cliff.”
http://dealbook.nytimes.com/2010/10/12/pfizer-to-buy-king-pharmaceuticals-for-3-6-billion/
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM